Contribution of SuPAR for Patients in a Situation of Uncertainty Downstream of Emergencies

SuPAR (Soluble urokinase Plasminogen Activator Receptor) is a non-specific prognostic blood biomarker related to inflammation. An elevated SuPAR value reflects significant chronic inflammation and predicts a risk of negative outcome and even short-term mortality (intra-hospital, 30 days, 90 days). Conversely, a low SuPAR value is a strong indicator of good prognosis and low risk of readmission. It is therefore of interest to know a patient's SuPAR blood level to enable the clinician to decide whether the patient should be admitted or discharged. SuPAR has been shown to be the best prognostic marker associated with the presence and progression of disease and risk of mortality. The use of SuPAR in clinical routine adds significant complementary information to the standard Early Warning Score assessment and to the classical parameters such as CRP, PCT, Lactate, ALT, Bilirubin, and CBC in the pre-admission of acute patients.

Patients admitted to the emergency department will receive their usual management. We will test the added value of the SuPAR assay in the prognosis of patients' outcome at discharge.

Inclusion criteria

• Patient, male or female, over 18 years old
• Admitted to the emergency department of the Clermont-Ferrand University Hospital for a medical reason,
• Classified as FRENCH II or III by the nurse organizer of the reception management
• Necessity of clinical observation in the Short Term Hospitalization Unit for final orientation decision
• Requires a blood test upon arrival in the emergency department
• Able to give informed non-opposition to participate in the research.
• Affiliation to a Social Security system

Exclusion criteria

• Patient under guardianship or curatorship
• Pregnant and breast feeding woman
• Patient admitted for psychiatric pathology
• Patient with a limitation of therapeutics
• Refusal to participate
• Patient hospitalized because of a particular social context